Klin Farmakol Farm. 2006;20(3):158-161

Serious acquired valvular defects following the use of anorectics-antidepressants - possible risks of long-term pharmacotherapy of obesity and depression

doc. MUDr. Juraj Hrnčiar CSc, František Kovář, Pavol Kmeč, Mária Hrnčiarová
Interná klinika, Nemocnica F. D. Roosvelta, Banská Bystrica

A case is reported of serious acquired aortic valve defect in a 51-year-old man who has never experienced rheumatic fever nor any other inflammatory disease of the endocardium. In the course of a long-term follow-up for WPW syndrome, the valvular defect was not present and it must have developed during the past four years when the patient used third generation SSRI antidepressants for two years as well as benzodiazepine anxiolytics (Xanax tablets). An overview of literature on acquired valvular defects following the use of anorectics-antidepressants is presented. Acquired valvular defects due to the action of excess serotonin in tissues seem to result not only from anorectics such as fenteramie and fenfluramie, but also from anorectics and antidepressants of the third generation acting by selective serotonin (SSRI) and norepinephrine (SNRI) reuptake inhibition at synapses and nerve endings in tissues; the literature, however, still fails to mention these risks.

Keywords: Key words: depression, obesity, anorectics, antidepressants, serotonin, acquired valvular defects.

Published: January 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hrnčiar J, Kovář F, Kmeč P, Hrnčiarová M. Serious acquired valvular defects following the use of anorectics-antidepressants - possible risks of long-term pharmacotherapy of obesity and depression. Klin Farmakol Farm. 2006;20(3):158-161.
Download citation

References

  1. Suchopár J, Šimek R, Valentová Š, Buršík J. Remedia compendium, II. vydanie, Panax 1997: s. 663.
  2. Gerattini S, Busco W, Jori A, et al. The mechanism of action of fenfluramine. Postgrad Med J 1975; 51 (suppl. 1), 27-35.
  3. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramin-phenteramine N Engl J Med. 1997; 337: 581-588. Go to original source... Go to PubMed...
  4. Caccitolo JA, Connolly HM, Rubenson DS, Orszulak TA, Schaff HV. Operation for anorexigen-assotiated valvular heart disease. J Thor Cardiovasc Surg 2001; 122: 656-664. Go to original source... Go to PubMed...
  5. Hrnčiar J, a kol. Endokrinné a hormonálno-metabolické choroby ich racionálna diagnostika a komplexná liečba. CM Centromedian B. Bystrica, 2000; s. 308.
  6. Hautzinger M. Depresia. Vydavateľstvo F, Trenčín 2000; s. 86.
  7. Heal DJ, Aspley S, Oriw MR, et al. Sibutramin a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamín and d-fenfluramín. Int. J. Obesity, 1998; 22: (supl. 1): 18-28.
  8. Gardin JM, Schumacher D, Davis G, et al. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phenteramine/fenfluramine. JAMA, 2000; 283: 1738-1740. Go to original source... Go to PubMed...
  9. Ewalenko M, Richard C, Vandenbossche JL. Fenfluramines and cardiac valvular lesions. Rev Med Brux 1999; 20: 419-26. Go to PubMed...
  10. Wong J, Ready SSK, Klein AL. Anorectic drugs and valvular heart disease. A biological and clinical perspektive. Cliv Clin Med J 1998; 65: 35-41. Go to original source... Go to PubMed...
  11. POTS Study (pediatric OCD treatment study). JAMA 2004, 292: 1969-1976. Go to original source... Go to PubMed...
  12. Connolly HM, Nishimura RA, Smith HC, et al. Outcome of cardiac surgery for carcinoid heart disease. J Am Coll Cardiol 1995; 25: 410-416. Go to original source... Go to PubMed...
  13. Thomas SH, Butti AY, Corris PA, et al. Appetite supresant and primary pulmonary hypertension in the United Kingdom. Br Heart J 1995; 74: 660-663. Go to original source... Go to PubMed...
  14. Abenheim L, Moride Y, Brenot F, et al. Appetite supressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 333: 609-616. Go to original source... Go to PubMed...
  15. Brenot F, Herve P, Petipretz P, et al. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993; 70, 537-541. Go to original source... Go to PubMed...
  16. Hauck AJ, Edwars WD, Danielson GK, et al. Mitral and aortic valve disease associated with ergotamine therapy for migraine: report of two cases and review of literature. Arch Pathol Lab Med 1990; 114: 62-64.
  17. Masson JW, Billinham ME, Fredman JP, et al. Methylsergide-induced heart disease a case of multivalvular and myocardial fibrosisi. Circulation 1977; 56: 889-890. Go to original source... Go to PubMed...
  18. Misch KA: Development of heart valve lesion during methylsergid therapy. BMJ 1974; 2: 365-366. Go to original source... Go to PubMed...
  19. Mast ST, Gersing KR, Anstrom KJ, et al. Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation. Am. J. Cardiol. 2001; 87: 989-993. Go to original source... Go to PubMed...
  20. Weissman NJ, Tighe JF, jr, Gottdiener JS, Gwyne JT. Prevalence of valvular regurgitation associated with dexfenfluramine three to five month after discontinuation of treatment. J Am Coll Cardiol. 1999; 34: 2088-2095. Go to original source... Go to PubMed...
  21. Shively BK, Roldan CA, Gill EA, et al. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation 1999; 23, 100: 2161-2167, komentár v: Circulation 2000; 102: E180. Go to original source... Go to PubMed...
  22. Kahn MA, Herzog CA, Peter JV st, et al. The prevalence of cardiac valvular insufficiency associated by transthoracic echocardiography in obese patients treated witth appetite-supressant drugs. N Engl J Med. 1988; 339: 713-718. Go to original source... Go to PubMed...
  23. Jick H, Vasilakis C, Weinrauch LA, et al. A population-based study of appetie-supressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med. 1988; 339: 719-724. Go to original source... Go to PubMed...
  24. Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europa: The Euro Heart Survey on Valvular heart Disease. Eur Heart J 2003; 24: 1231-1243. Go to original source... Go to PubMed...
  25. Passik CS. Temporal changes in the causes of aortic stenosis. A surgical pathologic study od 646 cases. Mayo Cli Proc 1987; 62: 119. Go to original source... Go to PubMed...
  26. Šimková J. Choroby aortálnej chlopne. Int Med 2006; 6: 14-19.




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.